Tovorafenib
- Generic Name
- Tovorafenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl2F3N7O2S
- CAS Number
- 1096708-71-2
- Unique Ingredient Identifier
- ZN90E4027M
- Background
Tovorafenib (TAK-580) is under investigation in clinical trial NCT02723006 (Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma).
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
- Conditions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Daniel Morgenstern
- Target Recruit Count
- 57
- Registration Number
- NCT06381570
- Locations
- π¨π¦
The Hospital for Sick Children, Toronto, Ontario, Canada
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanDrug: Tovorafenib
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT05828069
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
πΊπΈKaiser Permanente Downey Medical Center, Downey, California, United States
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
- Conditions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Registration Number
- NCT05760586
DAY101 Vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05566795
- Locations
- πΊπΈ
Children's Hospital of Orange County Main Campus - Orange, Orange, California, United States
πΊπΈUniversity of Florida Health, Gainesville, Florida, United States
πΊπΈUniversity of Nebraska Medical Center, Omaha, Nebraska, United States
Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Sabine Mueller, MD, PhD
- Target Recruit Count
- 56
- Registration Number
- NCT05465174
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈRady Children's Hospital/University of California, San Diego, San Diego, California, United States
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04985604
- Locations
- πΊπΈ
The Angeles Clinic, Los Angeles, California, United States
πΊπΈHoag Health, Newport Beach, California, United States
πΊπΈUniversity of Colorado Hospital, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.